Natera Inc.

Company Overview

Natera is a leading diagnostics company that provides proprietary molecular and bioinformatics technology-oriented products for disease management in the areas of oncology, women's health, and organ health. The company’s cell-free DNA (cfDNA) technology combines novel molecular assays that accurately measure numerous informative regions across the genome from samples as small as a single cell with statistical algorithms that incorporate data from the wider scientific community to identify variation in genes covering a wide range of serious conditions with high coverage and accuracy. To safeguard health and guide earlier, more precise interventions that contribute to longer, healthier lives, the company seeks to mainstream personalized genetic testing and diagnostics into the standard of care. Natera has a strong distribution network with a direct sales force and a global network of more than 100 laboratory and distribution partners for its products. The company boasts over 75 publications in the field of women’s health, 40 in oncology, and more than 20 in the field of organ health. To promote treatments that contribute to living longer, healthier lives, Natera has ISO 13485-certified and CAP-accredited laboratories in San Carlos, California, and Austin, Texas.

Financial Highlights (FY 2024)

Company's Business Segments

• Product Revenues : This segment generates revenues from the sale of tests, primarily from the sale of our Signatera, Panorama and HCS tests.
• Licensing and Other Revenues : This segment Revenues recognized from tests processed through our Constellation model, and from our strategic partnership agreements are reported in licensing and other revenues.